SAN DIEGO and VANCOUVER, British Columbia, June 23, 2017 /PRNewswire/ -- Sophiris Bio
Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a late stage
clinical biopharmaceutical company developing topsalysin (PRX302)
for the treatment of patients with urological diseases, today
announced that it has been added to the Russell
Microcap® Index, effective after the close of market
on June 23, 2017.
The Russell Microcap® Index represents 2,000 small
cap and micro-cap stocks that captures the smallest 1,000 companies
in the Russell 2000®, in addition to 1,000 smaller U.S.-
based listed stocks.
Russell indices are widely used by investment managers and
institutional investors for index funds and as benchmarks for both
passive and active investment strategies. Russell Investments
determines membership for each index based on objective market
capitalization rankings and style attributes.
Certain statements included in this press release may be
considered forward-looking. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on
Sophiris' current beliefs as well as assumptions made by and
information currently available to Sophiris and relate to, among
other things, anticipated financial performance, business
prospects, strategies, regulatory developments, market acceptance
and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by Sophiris in its
public securities filings; actual events may differ materially from
current expectations. Sophiris disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
About Sophiris
Sophiris Bio Inc. is a late stage clinical biopharmaceutical
company developing topsalysin (PRX302) for the treatment of
patients with urological diseases. Topsalysin is in Phase 2
clinical development for the focal treatment of localized prostate
cancer as well as Phase 3 clinical development for the treatment of
lower urinary tract symptoms of benign prostatic hyperplasia (BPH).
Topsalysin is a highly potent ablative agent that is selective and
targeted in that it is only activated by enzymatically active PSA
which is found in high concentrations in the transition zone of the
prostate and in and around prostate tumor cells. More than
400 patients have received treatment with topsalysin, which
continues to appear to be safe and well tolerated. For more
information, please visit www.sophirisbio.com.
Company Contact:
Peter
Slover
Chief Financial Officer
(858) 777-1760
Corporate Communications Contact:
Jason Spark
Canale Communications
(619) 849-6005
jason@canalecomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sophiris-bio-added-to-russell-microcap-index-300478727.html
SOURCE Sophiris Bio Inc.